Skip to main content
. 2016 Apr 16;7(19):28670–28683. doi: 10.18632/oncotarget.8764

Figure 4. FGFR2 activation augments CD44 signaling and CD44 activation enhances FGFR2 signaling.

Figure 4

A. Activation of the FGFR2 signaling axis by FGF7 (left) and transfecting FGFR2 expression vector into MKN45 (middle) or AGS gastric cancer cell lines, increased CD44 but decreased c-Myc. There was no discernible change in EGFR and HER2 in multiple gastric cancer cell lines. Note concomitant transient phosphorylation of ERK, a positive control marker of FGFR2 activation. B. CD44 activation increased CD44 and FGFR2. C. FGFR2 inhibitor PD173074 enhanced Sox2 and c-Myc mRNA levels. D. FGF7 treatment decreased Sox2 and c-Myc mRNA. E. Five different shRNAs (sets 1–5) mediating c-Myc KD decreased FGFR2 levels. KD of c-Myc by shRNA sets 3–5 also decreased CD44. F. Transfection of human c-Myc (pcDNA3-c-Myc) into MKN45 cells increased FGFR2 (*) and Sox2 mRNA (**), but not CD44 mRNA. Western blot of c-Myc expression shown in the inset.